Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)

• Status: Completed
• Trial end date: 2004-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a non-U.S. marketed formulation of ondansetron.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Ondansetron

Criteria

Inclusion Criteria:

• If female, subject is not pregnant or breast-feeding

• Subject has been a nonsmoker for at least 6 months

• Subject is in good health

Exclusion Criteria:

• Subject has a history of high blood pressure, asthma, other pulmonary disease, Gastrointestinal (GI) abnormalities/peptic ulcers, or cardiovascular, liver, neurologic, or kidney disease

• Subject is a habitual and heavy consumer of caffeine